Literature DB >> 10482689

Fas expression prevents cholangiocarcinoma tumor growth.

A Pickens1, G Pan, J M McDonald, S M Vickers.   

Abstract

Cholangiocarcinoma continues to have a dismal prognosis with an overall survival rate of less than 10%. An increased understanding of the molecular oncogenesis of this tumor is needed. Fas/APO-1 (CD95) receptor and Fas ligand have been implicated as key factors in apoptosis. In this study we have examined the role of the Fas receptor in the growth of cholangiocarcinoma. The purpose of this study was to evaluate the role of the Fas receptor in the induction of apoptosis in cholangiocarcinoma and to assess the role of the Fas receptor in cholangiocarcinoma tumorigenesis. Human cholangiocarcinoma cells, SK-ChA-1, were evaluated for Fas receptor expression using fluorescence-activated cell sorting (FACS). Distinct cell populations (Fas-positive and Fas-negative) were isolated by FACS and cloned from single cell dilutions. Fas expression was assessed by FACS and reverse transcriptase-polymerase chain reaction (RT-PCR). Cell populations were further characterized by their sensitivity to anti-Fas monoclonal antibody at 72 hours. Cell viability and apoptotic index were evaluated by trypan blue cell count and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL) assay, respectively. Distinct cell populations were evaluated for their ability to form tumors in BALB/c nude mice (2.5 x 10(6) cells per subcutaneous injection). After 4 weeks, tumors were evaluated for tumor area by caliper measurement and Fas expression by RT-PCR. Maintenance of biliary phenotype was assured by means of AE-1 (cytokeratin) immunohistochemistry. Populations of Fas-positive and Fas-negative cells were identified, isolated, and confirmed by FACS and RT-PCR. Treatment of Fas-positive cells with anti-Fas monoclonal antibody produced an 80% reduction in cell viability compared to no decrease in viability in Fas-negative cells by trypan blue cell count. TUNEL staining showed an apoptotic index of 75% for Fas-positive cells incubated with anti-Fas monoclonal antibody and no significant evidence of apoptosis in the Fas-negative cells. When cholangiocarcinoma cells were subcutaneously injected into nude mice, only Fas-negative cells formed tumor nodules; Fas-positive cells failed to form tumor nodules. The analyzed tumors lacked Fas messenger RNA by RT-PCR but maintained the biliary cytokeratin AE-1 by immunohistochemistry. Fas receptor expression is an important mediator of apoptosis in cultured human cholangiocarcinoma cells and appears to be a critical determinant of cholangiocarcinoma tumor growth in nude mice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482689     DOI: 10.1016/s1091-255x(99)80053-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  30 in total

1.  Tamoxifen-mediated growth inhibition of human cholangiocarcinoma.

Authors:  L K Sampson; S M Vickers; W Ying; J O Phillips
Journal:  Cancer Res       Date:  1997-05-01       Impact factor: 12.701

2.  Cellular events involved in the sensitization of etoposide-resistant cells by inhibitors of calcium-calmodulin-dependent processes. Role for effects on apoptosis, DNA cleavable complex, and phosphorylation.

Authors:  K Kawamura; D Grabowski; K Krivacic; H Hidaka; R Ganapathi
Journal:  Biochem Pharmacol       Date:  1996-12-24       Impact factor: 5.858

3.  Expression of Fas-Fas ligand system associated with atresia through apoptosis in murine ovary.

Authors:  T Mori; J P Xu; E Mori; E Sato; S Saito; M W Guo
Journal:  Horm Res       Date:  1997

4.  Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro.

Authors:  I F Pollack; M S Randall; M P Kristofik; R H Kelly; R G Selker; F T Vertosick
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

Review 5.  Clinical review 41: Current therapy for osteoporosis.

Authors:  R R Recker
Journal:  J Clin Endocrinol Metab       Date:  1993-01       Impact factor: 5.958

6.  Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells.

Authors:  F Leithäuser; J Dhein; G Mechtersheimer; K Koretz; S Brüderlein; C Henne; A Schmidt; K M Debatin; P H Krammer; P Möller
Journal:  Lab Invest       Date:  1993-10       Impact factor: 5.662

7.  Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women.

Authors:  R L Ward; G Morgan; D Dalley; P J Kelly
Journal:  Bone Miner       Date:  1993-08

8.  Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen.

Authors:  W T Couldwell; M H Weiss; C M DeGiorgio; L P Weiner; D R Hinton; G R Ehresmann; P S Conti; M L Apuzzo
Journal:  Neurosurgery       Date:  1993-03       Impact factor: 4.654

9.  Synergistic induction of apoptosis in breast cancer cells by tamoxifen and calmodulin inhibitors.

Authors:  O S Frankfurt; E V Sugarbaker; J A Robb; L Villa
Journal:  Cancer Lett       Date:  1995-11-06       Impact factor: 8.679

Review 10.  Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects.

Authors:  R R Love
Journal:  J Clin Oncol       Date:  1989-06       Impact factor: 44.544

View more
  2 in total

1.  Tamoxifen (TMX)/Fas induced growth inhibition of human cholangiocarcinoma (HCC) by gamma interferon (IFN-gamma).

Authors:  Selwyn M Vickers; Nirag C Jhala; Eun-Young Ahn; Jay M McDonald; George Pan; Kirby I Bland
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

2.  Primary and malignant cholangiocytes undergo CD40 mediated Fas dependent apoptosis, but are insensitive to direct activation with exogenous Fas ligand.

Authors:  Elizabeth H Humphreys; Kevin T Williams; David H Adams; Simon C Afford
Journal:  PLoS One       Date:  2010-11-17       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.